Search results
Showing 2851 to 2900 of 3803 results for treatment
them. During the consent process, patients should be told about all treatment options, and their advantages and disadvantages. ViV‑TAVI...
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Balloon kyphoplasty for vertebral compression fractures (HTG108)
Evidence-based recommendations on balloon kyphoplasty for vertebral compression fractures. This involves inflating baloon-like devices placed into the collapsed vertebra until it reaches normal height, after which they are removed and replaced with a special cement.
View recommendations for HTG108Show all sections
Sections for HTG108
Evidence-based recommendations on off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation. This involves inserting artificial chordae that help the mitral valve to close properly.
View recommendations for HTG772Show all sections
The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)
NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation
episode and established psychosis, relate to symptoms of psychosis and its treatment (including detention). One study has demonstrated...
the choice of treatment and the design of any future research. Psychological interventions for paraphilias (such as sex offender...
This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.
View quality statements for QS178Show all sections
Sections for QS178
- Quality statements
- Quality statement 1: Asking people about their sexual history
- Quality statement 2: Discussing prevention and testing with people who are at risk of sexually transmitted infections
- Quality statement 3: Condom distribution schemes
- Quality statement 4: Access to sexual health services
- Quality statement 5: Repeat testing for sexually transmitted infections
- Quality statement 6: Partner notification
- Update information
Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230)
Interventional procedures, IPG230 - Issued: August 2007 --> We have moved interventional procedures guidance 230 to become HealthTech guidance 148. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)
This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.
Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)
This guidance has been updated and replaced by NICE technology appraisal guidance 329.
when visual field testing is used alone. This could lead to escalation of treatment with less visual loss and blindness. However, it is...
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence
t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)
NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes .
Evidence-based recommendations on living-donor liver transplantation. This involves replacing a diseased or damaged liver with a healthy one from a living human donor.
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101.
Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101.
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)
This guidance has been updated and replaced by NICE technology appraisal guidance 432.
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]
In development Reference number: GID-TA11606 Expected publication date: TBC
uncertainties about side effects and effectiveness may contribute to the under-treatment of mental health problems in people with...
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]
In development Reference number: GID-TA11629 Expected publication date: TBC
life expectancy from other causes. Medicines and other treatments may therefore be adding to treatment burden without...
Pre-hospital initiation of fluid replacement therapy in trauma (TA74)
Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.
NICE has developed a medtech innovation briefing (MIB) on cyanoacrylate glue for hernia mesh fixation .
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)
This guidance has been updated and replaced by NICE technology appraisal guidance 373.
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Asking people about falls
- Quality statement 2: Comprehensive falls assessment
- Quality statement 3: Interventions to reduce the risk of falls
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
in guidelines for preventing future morbidity or mortality, including treatments for hypertension, hyperglycaemia and osteoporosis....
This guidance has been updated and replaced by NICE technology appraisal guidance 385.
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
This guidance has been updated and replaced by NICE technology appraisal guidance 766.
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
In development Reference number: GID-TA11365 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .
accurate prognosis will mean that more people are given the most effective treatment. The committee recommended the 5‑tier Cambridge...
Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)
Interventional procedures, IPG484 - Issued: March 2014 --> We have moved interventional procedures guidance 484 to become HealthTech guidance 337. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
This guidance has been updated and replaced by NICE technology appraisal guidance 1071.
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development Reference number: GID-TA10935 Expected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Discontinued Reference number: GID-TA11569
NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery .
In development Reference number: GID-TA11663 Expected publication date: TBC
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.
familial hypocalciuric hypercalcaemia (FHH) because it needs no operative treatment. Evidence showed that the 3 tests recommended are...
identified, therefore decisions on treatment can be made earlier in the diagnosis pathway saving on future treatment costs....
Comparator, Outcome) P: people hospitalised because of COVID-19 I: treatment with different doses of casirivimab and imdevimab C: •...